Edition:
India

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement


Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​. 

Company Quote

5.9
 --
14 Jun 2019